ticagrelor 90 mg
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ACS (Acute Coronary Syndrome)
Conditions
ACS (Acute Coronary Syndrome)
Trial Timeline
Mar 5, 2018 → Aug 13, 2019
NCT ID
NCT03444012About ticagrelor 90 mg
ticagrelor 90 mg is a pre-clinical stage product being developed by AstraZeneca for ACS (Acute Coronary Syndrome). The current trial status is completed. This product is registered under clinical trial identifier NCT03444012. Target conditions include ACS (Acute Coronary Syndrome).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03444012 | Pre-clinical | Completed |
Competing Products
6 competing products in ACS (Acute Coronary Syndrome)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC) | Astellas Pharma | Phase 2/3 | 65 |
| Roflumilast + Placebo | AstraZeneca | Phase 2 | 52 |
| milatuzumab | Gilead Sciences | Phase 1 | 32 |
| Conditioning Regimen A + Conditioning Regimen B + Conditioning Regimen C + Conditioning Regimen D + Conditioning Regimen E + PTCy (50 mg/kg D3, D4) + PTCy (25 mg/kg D3, D4) + Post-transplant Tacrolimus + Post-transplant Mycophenolate mofetil + Post-transplant Abatacept + Post-transplant Ruxolitinib + Supportive Care: Growth Factors + Supportive Care: Seizure prophylaxis + Supportive Care: Prophylaxis against infections | Incyte | Phase 2 | 49 |
| Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates | Rigel Pharmaceuticals | Approved | 77 |
| p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine | Inovio Pharmaceuticals | Phase 2 | 44 |